EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous dual-target magnetic resonance-guided focused ultrasound treatment for patients with tremor-dominant Parkinson’s disease

Rezida M. Galimova, Sergey N. Illarioshkin, Gulnara N. Akhmadeeva, Dinara I. Nabiullina, Felix F. Kashapov, Shamil M. Safin, Igor V. Buzaev, Dinara R. Teregulova, Yulia A. Sidorova, Olga V. Kachemaeva

Annals of Clinical and Experimental Neurology · 2024

DOI: 10.17816/acen.1085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, 2024. Verfasst von Rezida M. Galimova und 9 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non-invasive magnetic resonance-guided focused ultrasound (MRgFUS) is a new neurosurgical treatment option for tremor-dominant Parkinson’s disease (TDPD). Outcomes of ablation with dual targeting of two subcortical nuclei to improve functional treatment results are yet to be explored.

Aim

This study aimed to evaluate the safety and efficacy of MRgFUS with simultaneous unilateral ablation of two cerebral targets in patients with TDPD. Materials and methods. A total of 82 TDPD patients (20 women, 62 men; median age 65.0 [52.5; 70,0] years) received unilateral MRgFUS, i.e. ventrointermedial (VIM) nucleus thalamotomy and/or pallidothalamotractotomy (PTT). Motor symptoms, including tremor, were assessed using MDS-Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS-III). VIM, PTT, and VIM + PTT ablation was received by 34, 12, and 36 patients, respectively.

Results

After surgery, MDS-UPDRS-III score improved by 40.1% (30.2; 51.7) without early or late-onset serious complications. Tremor returned in 18 patients (all after VIM thalamotomy); 9 of them successfully underwent re-treatment 9–12 months after the first procedure. Simultaneous dual-target (VIM + PPT) intervention was successfully received by 36 patients without any serious complications. A total of 89.3% and 69.7% of patients remained relapse-free in the dual-target and single-target groups, respectively (p = 0.039).

Conclusion

Simultaneous dual-target (VIM and PTT) MRgFUS showed favorable safety and efficacy profiles and can be considered a symptomatic treatment option for TDPD patients.

Zitieren

APA

Galimova, R. M., Illarioshkin, S. N., Akhmadeeva, G. N., Nabiullina, D. I., Kashapov, F. F., Safin, S. M., Buzaev, I. V., Teregulova, D. R., Sidorova, Y. A., & Kachemaeva, O. V. (2024). Simultaneous dual-target magnetic resonance-guided focused ultrasound treatment for patients with tremor-dominant Parkinson’s disease. Annals of Clinical and Experimental Neurology. https://doi.org/10.17816/acen.1085

Vancouver

Galimova RM, Illarioshkin SN, Akhmadeeva GN, Nabiullina DI, Kashapov FF, Safin SM, et al. Simultaneous dual-target magnetic resonance-guided focused ultrasound treatment for patients with tremor-dominant Parkinson’s disease. Annals of Clinical and Experimental Neurology. 2024. doi:10.17816/acen.1085

BibTeX
@article{Galimova2024,
  author = {Galimova, Rezida M. and Illarioshkin, Sergey N. and Akhmadeeva, Gulnara N. and Nabiullina, Dinara I. and Kashapov, Felix F. and Safin, Shamil M. and Buzaev, Igor V. and Teregulova, Dinara R. and Sidorova, Yulia A. and Kachemaeva, Olga V.},
  title = {Simultaneous dual-target magnetic resonance-guided focused ultrasound treatment for patients with tremor-dominant Parkinson’s disease},
  journal = {Annals of Clinical and Experimental Neurology},
  year = {2024},
  doi = {10.17816/acen.1085}
}
Kostenlos starten →